The favorable tolerability and immunomodulatory effects observed in mdx mice suggest that CSPG4.CAR-T therapy may be a viable and scalable strategy for DMD patients and potentially other dystrophy-related cardiomyopathies. This evidence concerns the gene CSPG4 and Duchenne muscular dystrophy.